# US 2019/0314449 A1 · Cyclic dipeptides and wound healing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314449 A1
- Document ID: US20190314449A1
- Status: Published application
- Kind: A1
- Application number: 16/461,084
- Filed: 2017-11-16
- Published: 2019-10-17
- Earliest claimed: 2016-11-16
- Assignees: Board of Regents, The University of Texas System
- Inventors: Anand PRASAD
- Web page: https://patentgrep.com/patent/US20190314449A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/722: Chitin, chitosan
- A61K 33/30: Zinc; Compounds thereof
- A61K 38/05: Dipeptides
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition comprising a cyclo-dipeptide and use thereof for treatment of a wound. The cyclo-dipep-tide can be Cyclo-His-Pro and the pharmaceutical composition can suitable for topical application to a wound. The compositions can be used to treat a wound, reduce tissue damage in a wound, prevent and/or reduce oxidative damage in a wound, and/or reduce the amount of heme in a wound.

## Claims

### Claim 1

A wound care composition comprising an active ingredient comprising Cyclo-His-Pro.

### Claim 2 (depends on 1)

The wound care composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The would care composition of claim 1, wherein the composition is formulated for topical application onto a wound.

### Claim 4 (depends on 1)

The wound care composition of claim 1, wherein the Cyclo-His-Pro is the only active ingredient.

### Claim 5 (depends on 1)

The wound care composition of claim 1, wherein the composition further comprises an additional active ingredient selected from one or a combination of agents capable of moisturizing, increasing cellular uptake of compounds, increasing neovascularization, providing anti-microbial activity, elevating nitrogen monoxide levels, increasing Vascular Endothelial Growth Factor activity and/or concentration, enhancing re-epithelialization, and/or decreasing inflammation.

### Claim 6 (depends on 5)

The wound care composition of claim 5, wherein the agent capable of increasing cellular uptake of compounds is a hydrogel, increasing neovascularization is a hydrogel, providing anti-microbial activity is Cyclo-Leu-Pro, Cyclo-Phe-Pro, chitosan, and/or zinc oxide, elevating nitrogen monoxide levels is arginine, increasing Vascular Endothelial Growth Factor activity and/or concentration is arginine, enhancing re-epithelialization is zinc oxide, and/or decreasing inflammation is zinc oxide.

### Claim 7 (depends on 1)

The wound care composition of claim 1, wherein the composition further comprises one or more additional cyclic dipeptide(s).

### Claim 8 (depends on 7)

The wound care composition of claim 7, wherein the one or more additional cyclic dipeptide(s) comprise proline as at least one of the two amino acids.

### Claim 9 (depends on 1)

A method of treating a wound, the method comprising administering the composition of claim 1 to a subject having a wound.

### Claim 10 (depends on 1, 9)

The method of claim 9, wherein the composition of claim 1 is administered topically to the wound.

### Claim 11 (depends on 1)

A method of reducing tissue damage in a wound, the method comprising administering the composition of claim 1 to a subject having a wound.

### Claim 12 (depends on 1, 11)

The method of claim 11, wherein the composition of claim 1 is administered topically to the wound.

### Claim 13 (depends on 1)

A method of preventing and/or reducing oxidative damage in a wound, the method comprising administering the composition of claim 1 to a subject having a wound.

### Claim 14 (depends on 1, 13)

The method of claim 13, wherein the composition of claim 1 is administered topically to the wound.

### Claim 15 (depends on 1)

A method of reducing the amount of heme in a wound, the method comprising administering the composition of claim 1 to a subject having a wound.

### Claim 16 (depends on 1, 15)

The method of claim 15, wherein the composition of claim 1 is administered topically to the wound.

### Claim 17

A wound care composition comprising one or a combination of cyclic dipeptide(s) and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

The wound care composition of claim 17, wherein the one or a combination of cyclic dipeptide(s) comprises proline as at least one of the two amino acids.

### Claim 19 (depends on 17)

The wound care composition of claim 17, wherein the one or a combination of cyclic dipeptide(s) is one or a combination of: Cyclo-Ala-Pro; Cyclo-Arg-Pro; Cyclo-Asn-Pro; Cyclo-Asp-Pro; Cyclo-Cys-Pro; Cyclo-Glu-Pro; Cyclo-Gly-Pro; Cyclo-His-Pro; Cyclo-Ile-Pro; Cyclo-Leu-Pro; Cyclo-Lys-Pro; Cyclo-Met-Pro; Cyclo-Phe-Pro; Cyclo-Pro-Pro; Cyclo-Ser-Pro; Cyclo-Thr-Pro; Cyclo-Trp-Pro; Cyclo-Tyr-Pro; Cyclo-Val-Pro; and/or Cyclo-Gln-Pro.

### Claim 20 (depends on 17)

The would care composition of claim 17, wherein the composition is formulated for topical application onto a wound.

### Claim 21 (depends on 17)

The wound care composition of claim 17, wherein the composition further comprises an additional active ingredient selected from one or a combination of agents capable of moisturizing, increasing heme-scavenging, increasing cellular uptake of compounds, increasing neovascularization, providing anti-microbial activity, elevating nitrogen monoxide levels, increasing Vascular Endothelial Growth Factor activity and/or concentration, enhancing re-epithelialization, and/or decreasing inflammation.

### Claim 22 (depends on 21)

The wound care composition of claim 21, wherein the agent capable of increasing heme-scavenging is Cyclo-His-Pro, increasing cellular uptake of compounds is a hydrogel, increasing neovascularization is a hydrogel, providing anti-microbial activity is Cyclo-Leu-Pro, Cyclo-Phe-Pro, chitosan, and/or zinc oxide, elevating nitrogen monoxide levels is arginine, increasing Vascular Endothelial Growth Factor activity and/or concentration is arginine, enhancing re-epithelialization is zinc oxide, and/or decreasing inflammation is zinc oxide.

### Claim 23 (depends on 17)

A method of treating a wound, the method comprising administering the composition of claim 17 to a subject having a wound.

### Claim 24 (depends on 17, 23)

The method of claim 23, wherein the composition of claim 17 is administered topically to the wound.

### Claim 25 (depends on 17)

A method of reducing tissue damage in a wound, the method comprising administering the composition of claim 17 to a subject having a wound.

### Claim 26 (depends on 17, 25)

The method of claim 25, wherein the composition of claim 17 is administered topically to the wound.

### Claim 27 (depends on 17)

A method of preventing and/or reducing oxidative damage in a wound, the method comprising administering the composition of claim 17 to a subject having a wound.

### Claim 28 (depends on 17, 27)

The method of claim 27, wherein the composition of claim 17 is administered topically to the wound.

### Claim 29 (depends on 17)

A method of reducing the amount of heme in a wound, the method comprising administering the composition of claim 17 to a subject having a wound.

### Claim 30 (depends on 1, 29)

The method of claim 29, wherein the composition of claim 1 is administered topically to the wound.

### Claim 31 (depends on 17)

A method of reducing scarring of a wound, the method comprising administering the composition of claim 17 to a subject having a wound.
